Axelyf’s first grant from the Icelandic Centre for Research

Written By Örn Almarsson

June 5, 2023

Axelyf has been awarded its first grant from the Icelandic Centre for Research to investigate anti-inflammatory effects of BPH-555, an astaxanthin prodrug. The grant enables Axelyf to broaden its work on its lead compound to additional indications. The grant, which is in the Sprout (Sproti) category, is the Company's first non-dilutive funding.

Örn Almarsson
Previous

Örn Almarsson was interviewed in Iceland for The Iceland Monitor and discussed the founders' motivation and establishment of Axelyf
Next

Örn Almarsson joins Charles Spence on ‘A Dose of Reality’ podcast